These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3570783)

  • 1. [Behçet disease and exogenous interferon. A successful treatment study using recombinant alpha-A-IFN].
    Stadler R; Bratzke B; Baumann I
    Hautarzt; 1987 Feb; 38(2):97-100. PubMed ID: 3570783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Behçet disease].
    Stadler R; Bratzke B; Orfanos CE
    Hautarzt; 1987 Aug; 38(8):453-60. PubMed ID: 3654216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
    Kuzmits R; Scheithauer W; Ludwig H; Flener R
    Acta Med Austriaca; 1985; 12(5):129-34. PubMed ID: 3938590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alpha interferon in condylomata acuminata and juvenile diabetes mellitus].
    Gross G; Roussaki A; Ikenberg H; Drees N
    Dtsch Med Wochenschr; 1986 Sep; 111(36):1351-5. PubMed ID: 3743447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid improvement in a terminal case of hairy cell leukemia treated with a new human recombinant interferon, IFN-alpha-C.
    Aderka D; Levo Y; Rahmani R; Mory Y; Vaks B; Horowitz O; Doerner T; Shoham J; Wallach D; Revel M
    Isr J Med Sci; 1985 Dec; 21(12):977-81. PubMed ID: 4093298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome.
    Kiliç H; Zeytin HE; Korkmaz C; Mat C; Gül A; Coşan F; Dinç A; Simşek I; Süt N; Yazici H
    Rheumatology (Oxford); 2009 Nov; 48(11):1388-91. PubMed ID: 19717547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha treatment of Behçet's disease.
    O'Duffy JD; Calamia K; Cohen S; Goronzy JJ; Herman D; Jorizzo J; Weyand C; Matteson E
    J Rheumatol; 1998 Oct; 25(10):1938-44. PubMed ID: 9779847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of renal cell carcinoma. 3. Interferon therapy].
    Kobayashi M; Imai K; Kiren H; Nakai K; Saruki K; Umeyama T; Ito Y; Yamanaka H; Makino T; Machida M
    Hinyokika Kiyo; 1987 Apr; 33(4):508-14. PubMed ID: 3618421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
    Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intralesional alpha 2-interferon on actinic keratoses.
    Edwards L; Levine N; Weidner M; Piepkorn M; Smiles K
    Arch Dermatol; 1986 Jul; 122(7):779-82. PubMed ID: 3524471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on interferon in Behçet's disease].
    Kato F
    Hokkaido Igaku Zasshi; 1983 Jan; 58(1):63-73. PubMed ID: 6404745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris.
    Vance JC; Bart BJ; Hansen RC; Reichman RC; McEwen C; Hatch KD; Berman B; Tanner DJ
    Arch Dermatol; 1986 Mar; 122(3):272-7. PubMed ID: 3954392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon alpha 2C in the treatment of 2 patients with AIDS-associated Kaposi sarcoma].
    Steger G; Dittrich C; Eichler HG; Flener R; Moser K
    Wien Klin Wochenschr; 1987 Feb; 99(4):120-3. PubMed ID: 3577187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of multiple sclerosis with various interferons: the cons.
    Johnson KP
    Neurology; 1988 Jul; 38(7 Suppl 2):62-5. PubMed ID: 3133576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of interferon alpha 2A treatment in Behçet's disease.
    Boyvat A; Sişman-Solak C; Gürler A
    Dermatology; 2000; 201(1):40-3. PubMed ID: 10971058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma.
    Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Israel L; Falcoff E; Schwab D; Pouillart P
    Cancer; 1986 Jul; 58(2):215-8. PubMed ID: 3719515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New therapeutic prospectives in Behçet's disease: beta-interferon].
    Tata F; Gori E; De Bartolomeis AM; Mari MV
    Recenti Prog Med; 1988 Mar; 79(3):135-7. PubMed ID: 3393721
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
    Rinehart J; Malspeis L; Young D; Neidhart J
    Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of interferon-alpha in a case with Behçet's disease.
    Aoki T; Tanaka T; Akifuji Y; Ueki J; Nakamura I; Nemoto R; Ito K
    Intern Med; 2000 Aug; 39(8):667-9. PubMed ID: 10939544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.